3 mL) for 1 h at 37[degrees]C, unbroken cells and cell debris were removed by centrifugation at 3,500 rpm for 10 min, and
hemolysis was determined by the absorbance at 540 nm in supernatants.
The award - presented by the leading global medical technology company BD - recognized Sarasota Memorial for developing state-of-the-art processes and procedures designed to prevent
hemolysis in patient blood samples sent to the clinical laboratory for testing.
At the same time, STC, RTC and trolox suppressed oxidative
hemolysis of red blood cells (RBC) less efficiently than carnosine taken in the same concentration.
In addition to severe thrombocytopenia, he also had renal dysfunction, hypotension and
hemolysis.
When blood specimens are unusable because of
hemolysis, critical time and patient-care resources must be redirected to obtain repeat blood draws.
Since the substances that decrease reduced glutathione and membrane stability (by oxidation) are responsible for
hemolysis in G6PD deficiency, I am interested to learn the reasoning for the oseltamivir reaction if it caused
hemolysis?
The study showed that after 38 weeks of Soliris treatment, all patients with chronic kidney disease (CKD), a clinical consequence of chronic
hemolysis, either stabilized or improved.
In patients with PNH,
hemolysis can cause life-threatening thromboses, recurrent pain, kidney disease, disabling fatigue, impaired quality of life, severe anemia, pulmonary hypertension, shortness of breath and intermittent episodes of dark-colored urine (hemoglobinuria).
Her hematologic evaluation for anemia revealed severe intravascular
hemolysis.
Most authors describe three major causes of uremic anemia: blood loss,
hemolysis and shortened red cell survival, and failure of the bone marrow to produce new red cells (Schreiner & Maher, 1961; Brest & Moyer, 1967; Adamson, Eschbach, & Finch, 1968).
Using the model of free radical induced lysis of red blood cells it was established that the herbal-nutrient complex significantly delayed
hemolysis ([T.
Soliris(R) (eculizumab) therapy reduced
hemolysis, fatigue, thromboses (blood clots) and transfusion requirements in patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), including those who might have been expected to have less severe disease, according to data from an ongoing open-label clinical study presented today at the 49th Annual Meeting of the American Society of Hematology Meeting in Atlanta.
